Trutek Corp. Expands Reach in the European Market with Drug-Free Cold & Flu Block and Allergy Relief Products
Trutek Corp., an R&D and intellectual properties company, has begun further expansion into the European market with their innovative drug-free products, NasalGuard Allergie Block and NasalGuard Cold & Flu Block.
- (1888PressRelease) July 27, 2010 - Somerville, N.J. - Trutek Corp., an R&D and intellectual properties company, has begun further expansion into the European market with their innovative drug-free products, NasalGuard Allergie Block and NasalGuard Cold & Flu Block. The recent trademark of Allergie Block and registration of Cold & Flu Block in the European market will further enhance Trutek's efforts to build sales and brand awareness while promoting the company's dedication to solving real world health and wellness issues.
The registration filing of NasalGuard Cold & Flu Block in Europe is a monumental step for Trutek as this product creates a new trade category of virus prevention products. The Cold & Flu Block has received medical device registration from The Medicines and Healthcare products Regulatory Agency (MHRA) as well as Conformité Européenne (CE) designation, certifying that the product has met European consumer safety, health and environmental requirements. In addition, Trutek has filed for trademark application for NasalGuard Cold & Flu Block.
While the Cold & Flu Block was just recently registered and will be marketed soon, Trutek's Allergie Block had previously received Community Trade Mark (CTM) registration in the European Union and is currently being sold in France, Italy, Spain, and Portugal. Trutek is currently evaluating possible business partners to launch the Cold & Flu virus prevention products in Europe.
NasalGuard Allergie Block and NasalGuard Cold & Flu Block are both drug-free topical gels for nasal application. While Allergie Block prevents the inhalation of airborne allergens and Cold & Flu Block minimizes the inhalation of viruses. NasalGuard Cold & Flu Block has been tested and proven to entrap 94% to 97% of viruses including the common cold, avian flu and H1N1.
"Trutek's expansion into the European market is an extremely exciting opportunity for the company," said Vir Narula, Chief Operating Officer of Trutek Corp. "With the success of our allergy prevention products already well established in a number of countries, including the United States and Japan, we feel that the virus prevention products will have a much greater reach as many more consumers are affected by the common cold and flu. Although only a small percentage of the total world population suffers from seasonal allergies, everyone is exposed to viruses. The worldwide spread of both the H1N1 and Avian flu viruses demonstrates the immediate consumer need for this product."
For more information on NasalGuard and Trutek Corp., please visit: www.allergieblock.com or www.trutekcorp.com.
About Trutek Corp.
Trutek Corp., based in Somerville, NJ, was founded in 1995 and is dedicated to providing solutions to problems common to everyday life. Trutek is the owner of the technology and intellectual property for the NasalGuard® product line. Trutek currently has an extensive pipeline of additional technologies and products, and is seeking qualified licensees and joint venture partners. For more information, contact vnarula ( @ ) nasalguard dot com
Media Contact:
Angeline Boyer
R&J Public Relations
Phone: (908) 722-5757
aboyer ( @ ) randjpr dot com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam